Drug delivery company Lipidor, 50% owned by Karolinska Development, has reported positive results from Phase I/IIa psoriasis study of Akvano/calcipotriol spray formulation, a water-free spray formulation containing vitamin D derivative calcipotriol.
A total of 24 psoriasis vulgaris patients administered Akvano/calcipotriol spray formulation, in the study demonstrated clear and significant antipsoriatic effects compared with placebo, comparable to a marketed formulation of calcipotriol.
The patients in the study, which met the primary objective, received ten topical treatments over a 12-day period and reported no safety issues.
The primary objective of the Phase I/IIa clinical trial was met as AKVANO/calcipotriol showed clear and significant.
Antipsoriatic effects in the trial were measured by sonography as a reduction in infiltrate thickness, in comparison to corresponding vehicle formulations.
The study also met the secondary objective since the antipsoriatic effects were comparable to that of the marketed product Daivonex solution.
Commenting on the results, Lipidor CEO Anders Carlsson said: "The positive study results represents an important milestone for Lipidor in its efforts to develop a product with equivalent clinical efficacy compared to market leading calcipotriol-only topical treatments, and with superior cosmetic qualities and greater ease of use, thereby, improving compliance rates and patient quality of life."
Lipidor’s Akvano technology enables efficient delivery of the pharmaceutical ingredient.
The company claimed that after application the carrier compounds evaporates quickly, leaving a pleasant feeling on the skin and a cosmetically appealing result.
